New drug aims to tame eye inflammation in uveitis patients

NCT ID NCT07547995

Recruiting now Disease control Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests a new drug, GenSci048, in people with active non-infectious uveitis, an inflammatory eye disease. The trial will compare two doses of GenSci048 against a placebo to see if it can control the disease and reduce treatment failure. About 111 adults with active uveitis will participate, and the main goal is to measure how many avoid worsening of their condition over 25 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GenSci048
What this could lead to: If successful, this could provide a new treatment option to control active non-infectious uveitis, potentially reducing the need for high-dose steroids.
What could go wrong: This is an early Phase 2 trial with only 111 participants, so results may not apply to all patients. The drug may not prove more effective than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-INFECTIOUS INTERMEDIATE UVEITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intermediate uveitis panuveitis posterior uveitis uveitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UVEITIS

Contacts and locations

Locations

Eye & Ent Hospital of Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200031, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.